Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & Administrative
Others
Ratios

AC Immune (ACIU) EBITDA (2016 - 2025)

Historic EBITDA for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to -$20.2 million.

  • AC Immune's EBITDA fell 34086.85% to -$20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.4 million, marking a year-over-year decrease of 10689.5%. This contributed to the annual value of -$59.8 million for FY2024, which is 109.61% up from last year.
  • AC Immune's EBITDA amounted to -$20.2 million in Q3 2025, which was down 34086.85% from -$23.4 million recorded in Q2 2025.
  • AC Immune's 5-year EBITDA high stood at $8.4 million for Q3 2024, and its period low was -$24.7 million during Q4 2021.
  • For the 5-year period, AC Immune's EBITDA averaged around -$18.1 million, with its median value being -$20.4 million (2022).
  • The largest annual percentage gain for AC Immune's EBITDA in the last 5 years was 14791.54% (2024), contrasted with its biggest fall of 43239.11% (2024).
  • Quarter analysis of 5 years shows AC Immune's EBITDA stood at -$24.7 million in 2021, then grew by 21.47% to -$19.4 million in 2022, then skyrocketed by 79.43% to -$4.0 million in 2023, then tumbled by 432.39% to -$21.3 million in 2024, then grew by 4.91% to -$20.2 million in 2025.
  • Its EBITDA was -$20.2 million in Q3 2025, compared to -$23.4 million in Q2 2025 and -$21.5 million in Q1 2025.